FoldSight Bio provides the Iodination Protein Stability Assay (IPSA) for pharmaceutical laboratories to precisely measure protein shape and stability. This high-resolution biotechnology assay identifies in-vivo protein interactors and their interaction strength, supporting drug discovery and development.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical laboratories require precise methods to determine protein shape and stability, which are critical for drug discovery and development. Existing techniques may lack the resolution or applicability across a broad range of protein types, hindering comprehensive analysis.
Solution
FoldSight Bio offers the Iodination Protein Stability Assay (IPSA), a novel biotechnology solution designed to enhance protein analysis in pharmaceutical research. IPSA provides a high-resolution method for assessing protein structure and stability, enabling researchers to identify in-vivo protein interactors and the strength of their interactions with potential drug candidates. This assay supports the development of more effective therapeutics by offering detailed insights into biomolecular behavior.
Target Audience
The primary customers are pharmaceutical laboratories and academic research institutions focused on drug discovery, proteomics, and structural biology.
Features
- Iodination Protein Stability Assay (IPSA) for determining protein shape and stability.
- Capable of detecting 85% of protein types and resolving atoms on proteins with 10% accuracy.
- Detects proteins with surface-accessible histidine, tyrosine, methionine, and cysteine residues.
- Applicable to 75% of proteins found in biological samples.
- Utilizes iodination techniques, including radioiodination and non-radioactive methods, to probe structural dynamics and enhance imaging.
- Provides data on in-vivo protein interactors and interaction strength.